Quarterly ResultMay 15, 2026, 04:18 PM
Hoth Therapeutics Q1 Net Loss Narrows to $2.69M
AI Summary
Hoth Therapeutics reported a net loss of $2.69 million for the first quarter of 2026, an improvement from $3.48 million in the prior year. Despite the reduced loss, the company's cash and cash equivalents decreased to $4.05 million, and it continues to incur significant operating losses, leading to a going concern warning. To address funding needs, Hoth Therapeutics raised $701,484 through an At The Market offering during the quarter and an additional $1.61 million net from a securities purchase agreement in April 2026.
Key Highlights
- Net loss for Q1 2026 was $2.69 million, an improvement from $3.48 million in Q1 2025.
- Cash and cash equivalents decreased to $4.05 million as of March 31, 2026, from $6.25 million at Dec 31, 2025.
- Net cash used in operating activities increased to $3.05 million in Q1 2026 from $2.79 million in Q1 2025.
- Research and development expenses decreased to $1.52 million in Q1 2026 from $1.96 million in Q1 2025.
- General and administrative expenses decreased to $1.13 million in Q1 2026 from $1.52 million in Q1 2025.
- Raised $701,484 net from common stock sales via ATM offering during Q1 2026.
- Secured $1.61 million net from a securities purchase agreement in April 2026, selling 2.86M shares and warrants.
- Company issued a going concern warning, citing insufficient cash for the next 12 months.
Price Impact
More from HOTH